NCT05124925View on ClinicalTrials.gov

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

June 26, 2024

Study Completion Date

June 16, 2026

Conditions
Sjogren Syndrome
Interventions
BIOLOGICAL

Ianalumab

Ianalumab VAY736 150mg/1ml Solution for injection

Trial Locations (1)

29200

Novartis Investigative Site, Brest

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY